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Abstract 
Objectives: To elucidate the association between nerve growth factor (NGF) level and bladder pain syndrome/inter‑
stitial cystitis (BPS/IC) by conducting a meta‑analysis.
Methods: We conducted a systematic literature search to identify original studies of NGF level in BPS/IC before 
November 2015. Eligible studies were retrieved via both computer searches and manual review of references. The 
summary difference estimates between controlled group and BPS/IC group were calculated based on the weighted 
mean difference (WMD) with its 95 % confidence interval (CI). Sensitivity and publication analyses were performed 
after the pooled analysis.
Results: Meta‑analysis of 10 original studies involving 295 cases and 290 normal controls showed an increased level 
of urinary NGF in BPS/IC patients (z = 3.08, P = 0.002). The combined WMD was 36.39 (95 % CI 13.27–59.51). There 
was significant difference between controlled group and BPS/IC patients in the term of NGF/Cr level (WMD = 0.96, 
95 % CI 0.58–1.35; z = 4.89, P < 0.01). There was no significant publication bias in the included studies (P for Begg’s 
test = 0.73, P for egger’s test = 0.13).
Conclusions: Our results demonstrated that there was an increased level of NGF in the BPS/IC patients.
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Background
Bladder pain syndrome/interstitial cystitis (BPS/IC) is 
one of the most common chronic disorders of urinary 
bladder (Bosch and Bosch 2014). The mainly clinical 
manifestation is urgency and frequency with or without 
bladder pain. Nowadays, some methods for treatment 
of this disorder have been applied by doctors, while the 
long-term effect of these methods remains controversy 
(Diniz et  al. 2013). Early and non-invasive diagnosed 
method has been put forward in recent years. In these 
methods, the biomarkers in urinary are the hottest topic 
discussed. Recent studies showed that nerve growth fac-
tor (NGF) is a biomarker which could lead to overac-
tive bladder (OAB) and interstitial cystitis or bladder 
pain (Liu et  al. 2014; Jiang et  al. 2013, 2014). However, 
the results between studies were inconsistent (Seth et al. 
2013; Wein 2014; Ochodnicky et  al. 2011). In response, 
we conducted the first meta-analysis by pooling together 
the results from all published original studies. Our pur-




We aimed to identify all publications reporting urinary 
NGF level in BPS/IC patients. Our literature search was 
conducted with a systematic literature search before 
November 2015. The study was in accordance with 
meta-analysis of observational studies in epidemiology 
(MOOSE) guidelines (Vandenbroucke 2009). The data-
bases included PubMed, MEDLINE, Springerlink, Scien-
ceDirect, Chinese National Knowledge Internet (CNKI) 
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and EMBASE. The search strategies in our analysis were 
as following:
#1. (nerve growth factor) OR NGF OR NGFs.
#2. (bladder pain syndrome) OR interstitial cystitis OR 
BPS OR IC OR BPS/IC OR bladder disease.
#3. #1 and #2.
There was no any language restriction of our litera-
ture retrieve, while the trial objective should restrict as 
human. In order to screening additional relevant data, all 
the potential related references after paper were manu-
ally searched. The manual retrieve procedure was per-
formed by two independent investigators. Any ambiguity 
among the researchers was resolved by consensus and 
original data.
Criteria for inclusion and exclusion
The mainly included criteria for our study were as follow-
ing: (1) the study should be an original research, which 
mentioned the urinary NGF level in BPS or IC patients. 
(2) the primary outcome of NGF level was presented 
as continuous data, which can be collected to make a 
pooled quantitative analysis. (3) there was controlled 
group and corresponding quantitative data in original 
study. The exclusion criteria were: (a) there was no usable 
data reported. (b) duplicates data. (c) reviews, narrate or 
comments. (d) letters to editors, abstracts in conference 
or non-peer-reviewed journals.
Data extraction
Two reviewers independently extracted information from 
each article using standard forms, the extracted data con-
cerned first author, year of publication, location of the 
study, sample size in controlled group and BPS/IC group, 
mentioned outcome measures and baseline character-
istics. When more than one data were presented in the 
same study, we separately treated them as different study 
once the data were no cross effect between different con-
trolled group or different BPS/IC group. Any disagree-
ments were resolved by consensus. The primary outcome 
was urinary nerve growth factor.
Quality assessment
The eligibility of each study was assessed independently 
by two investigators. We assessed the methodological 
quality of the studies by means of the previously pub-
lished recommendations for systematic reviews of obser-
vational studies. The key points of the current checklist 
included the following terms: maintenance of compara-
ble groups, baseline of demography, study design, aim of 
the study, discussion of possible confounders, data col-
lection and bias. Any study that met fewer than four cri-
teria present should be excluded.
Statistical analysis
All the statistical procedure were performed in STATA 
software version 12.0 (STATA, College Station, TX, 
USA). The weighted mean difference (WMD) was used 
in the evaluation of difference urinary NGF level between 
controlled group and BPS/IC group. Moreover, the 
WMD also used in the evaluation of ratio of NGF and 
serum creatinine (Cr). The 95 % confidence interval (CI) 
of WMD was calculated to identify the study outcome 
variation. It is considered statistically significant for out-
come measure when the 95 % CI excluded zero. Hetero-
geneity was assessed by the Cochran’s Q test, with a 10 % 
significance level. On the other hand, the I2 statistic was 
adopted to interpret the degree of heterogeneity. A fixed 
effect model was performed in the data comparison sec-
tion unless the heterogeneity degree was I2  >  50  %, in 
which case a random effects approach was used to adjust 
for the combined estimate. Potential publication bias was 
assessed by Egger’s line regression and Begg’s funnel plot. 
Sensitivity analysis was performed by excluding the older 
studies. For all meta analyses, two side P < 0.05 was con-
sidered statistically significant.
Results
A total of 437 articles were retrieved initially, there were 
398 papers were did not in line with our inclusion crite-
ria, 11 relative papers were exclusion after read the titles 
and abstracts. 7 papers of remained 28 studies report the 
results only with figure, 7 papers report the data with 
unmergeable results, and data in the other 4 studies were 
incorrect or unbelievable due to their primary designs. 
Finally, we identified a total of ten studies (Baykara et al. 
2003; Liu and Kuo 2007; Liu et  al. 2009, 2010; Boudes 
et  al. 2011; Chung et  al. 2011; Liu and Kuo 2012; Tyagi 
et  al. 2012; Jiang et  al. 2013, 2014) mentioned urinary 
NGF level in BPS/IC patients according to our above 
mentioned criteria. A detail flow diagram of our search 
and selection was shown in Fig.  1. Characteristics and 
quality assessment of these studies are summarized in 
Table 1.
295 cases and 290 controlled participants were involv-
ing in our study. The number of original BPS/IC patients 
was ranged from 6 to 58, and the number of controlled 
participants was range from 5 to 33. There was no gen-
der, age or body mass index (BMI) dividing in 10 stud-
ies. Thus our study cannot make subgroup analysis based 
on these demographic characteristics. Of all the included 
studies, seven studies (Liu and Kuo 2007; Liu et al. 2009, 
2010; Chung et  al. 2011; Liu and Kuo 2012; Jiang et  al. 
2014) were conducted in Taiwan, China. One (Tyagi et al. 
2012) study was from USA, one study (Baykara et  al. 
2003) from Turkey and the other one was in Belgium 
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(Boudes et  al. 2011). The range of publication year was 
range from 2003 to 2014.
Ten studies reported the urinary NGF level in BPS or 
IC patients. In the selected studies, BPS or IC patients 
seemed to have a high urinary NGF level when com-
pared with controlled participants (WMD = 36.39, 95 % 
CI 13.27–59.51; z = 3.08, P = 0.002), Fig. 2 showed the 
difference of urinary NGF level in BPS/IC group and 
controlled group. Eight studies mentioned the ratio of 
urinary NGF and Cr. In the selected studies, the level of 
NGF/Cr was significant higher in BPS/IC patients when 
compared with controlled participants (WMD  =  0.96, 
95 % CI 0.58–1.35; z = 4.89, P < 0.01), Fig. 3 showed the 
difference of NGF/Cr level in BPS/IC group and con-
trolled group.
We also conducted a sensitivity analysis to investi-
gate the robustness of our findings. In our analysis, we 
excluded the oldest study published by Mehmet Baykara 
in 2003. The result showed that the difference between 
groups was as same as previous (WMD = 39.80, 95 % CI 
15.13–64.48; z = 3.16, P = 0.002).
We were able to assess publication bias in the primary 
outcome. The degree of asymmetry was not statistically 
significant by both Begg’s test and Egger’s line regression 
(P for Begg’s test =  0.73, P for egger’s test =  0.13). The 
Begg’s funnel plot was shown in Fig. 4.
Discussion
It is well-known that the non-invasive diagnostic method 
of urinary tract disorder is rapidly development in recent 
years. The most common method is the urinary bio-
marker in the diagnosis (Rubio-Diaz et  al. 2009). There 
are various biomarkers which included nerve growth fac-
tor and nuclear matrix protein. The level of NGF in blad-
der pain and interstitial cystitis were inconsistent among 
previous studies.
We have pooled all available related evidence to discuss 
the diagnostic value of NGF in BPS/IC through the meta-
analysis method (Seth et al. 2013; Liu et al. 2009). In this 
analysis, we identified that serum NGF level and NGF/Cr 
level in BPS/IC patient were significantly higher than that 
in controlled participants.
Recent investigations into the pathophysiology of BPS/
IC have demonstrated elevated levels of several bladder 
and urinary biomarkers in this bladder disorder, such 
as nerve growth factor (NGF) (Ochodnicky et  al. 2011; 
Chung et  al. 2011). Urinary NGF is produced from the 
Fig. 1 Study selected flow diagram
Table 1 Basic characteristics of included studies
NGF nerve growth factor, NGF/Cr ratio of nerve growth factor and creatinin
Author Year Region Sample size Outcome Study design Quality
BPS/IC Control
Hsin‑Tzu Liu 2012 Taiwan 30 28 Urinary NGF, NGF/Cr Compared 6
Pradeep Tyagi 2012 USA 10 10 Urinary NGF Compared 5
Mehmet Baykara 2003 Turkey 9 7 Urinary NGF Compared 5
Hsin‑Tzu Liu 2007 Taiwan 19 19 Urinary NGF Compared 6
Hsin‑Tzu Liu 2009 Taiwan 58 28 Urinary NGF, NGF/Cr Compared 5
Chia‑Yen Chen 2010 Taiwan 28 28 Urinary NGF, NGF/Cr Compared 6
Chia‑Yen Chen 2010 Taiwan 28 28 Urinary NGF, NGF/Cr Compared 6
Shiu‑Dong Chung 2011 Taiwan 22 33 Urinary NGF, NGF/Cr Compared 5
Shiu‑Dong Chung 2011 Taiwan 22 33 Urinary NGF, NGF/Cr Compared 5
Mathieu Boudes 2011 Belgium 6 5 Urinary NGF Compared 5
Yuan‑Hong Jiang 2013 Taiwan 30 26 Urinary NGF Compared 5
Yuan‑Hong Jiang 2014 Taiwan 33 45 Urinary NGF, NGF/Cr Compared 5
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urothelium and bladder smooth muscles. Patients with 
idiopathic detrusor overactivity, neurogenic bladder or 
inflammatory bladder diseases such as BPS/IC have been 
reported to have increased bladder sensation and urinary 
NGF levels (Jiang et al. 2013). NGF is responsible for the 
growth and maintenance of sensory neurons and appears 
Fig. 2 Meta‑analysis of urinary NGF in the diagnosis of BPS/IC. The size of the square is proportional to the percent weight of each study in the 
meta‑analysis; the horizontal lines represent 95 % CI
Fig. 3 Meta‑analysis of urinary NGF/Cr in the diagnosis of BPS/IC. The size of the square is proportional to the percent weight of each study in the 
meta‑analysis; the horizontal lines represent 95 % CI
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to play a role in neuroimmune interactions, in tissue 
inflammation, and in neuroplasticity for neuronal events 
leading to OAB (Chung et al. 2011).
To the best of our knowledge, there is no a comprehen-
sive assessment of the relation between NGF levels and 
the incidence of BPS/IC. This is the first meta-analysis 
of original studies on the potential relationship between 
NGF levels and the incidence of BPS/IC. Here, we pooled 
ten studies involving 585 participants to get a more sta-
ble and creditable result. The results suggested there was 
an increased level of NGF in the BPS/IC patients. To be 
noted, no substantial heterogeneity was detected in those 
studies included in our present analysis. On the basis of 
Egger’s and Begg’s tests, we have shown an absence of 
publication bias in these meta-analyses. In addition, sen-
sitivity analyses showed none of the studies considerably 
affected the summary associations between NGF levels 
and the incidence of BPS/IC.
Data are liable to be confounded by many factors, 
which could be reflected by the heterogeneity among 
studies. Firstly, our meta-analyses were based on the 
overall category of IC/BPS, we cannot distinguishing the 
subtypes based on the original study. Secondly, the pub-
lication year between studies were significant different. 
We know that the detection rates of NGF were different 
in different year because of the difference of awareness 
and assay technique of these diseases, even though with 
a same diagnostic standard. Thirdly, most of the studies 
are coming from the same study group (Liu HT, Jiang YH 
and Chung SD). While we have checked that the patients 
in the different studies were not the same, and the data 
in different studies were independent. Fourth, study with 
small sample size also can lead to this heterogeneity. The 
heterogeneity was inevitably significant when merging 
such a confidence interval. Finally, our study relies on 
nonrandomized and retrospective data. These reasons 
also could lead to potential bias of our result.
In summary, our meta-analysis of all relevant origi-
nal studies showed a significant increase level of NGF 
in BPS/IC patients. While the further studies are also 
required to better confirm the findings.
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